Sophiris shares rally on promising cancer treatment study

Sophiris Bio Inc.
SPHS, +1.33%
shares surged in the extended session Thursday after the tiny biotech's prostate cancer treatment showed promising results in a mid-stage clinical study. Sophiris shares rallied 74% to $2.04 on heavy volume after hours. The company said its treatment topsalysin showed an ability to destroy tumor cells in nine out of the 18 prostate cancer patients treated in a clinical study. "These promising early results open up the possibility of treating early prostate cancer by the simple administration of an injection into the prostate - something that could be done in an office setting," said Mark Emberton, an investigator on the study, in a statement.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.